Equities

Sygnis SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SYG:WSE

Sygnis SA

Actions
  • Price (PLN)2.18
  • Today's Change0.08 / 3.81%
  • Shares traded89.33k
  • 1 Year change+357.98%
  • Beta0.7581
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sygnis SA is a Poland-based company primarily engaged in the Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.

  • Revenue in PLN (TTM)7.73m
  • Net income in PLN-6.34m
  • Incorporated2011
  • Employees12.00
  • Location
    Sygnis SAul. Zwirki i Wigury 101WARSZAWA 02-089PolandPOL
  • Phone+48 226684757
  • Fax+48 587396441
  • Websitehttps://sygnis.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stem Cells Spin SA115.74k-510.92k18.19m1.00--2.7813.94157.15-0.0124-0.01240.00280.15810.01030.0083.43115,740.00-4.52-1.02-4.57-1.0595.9193.18-441.44-50.721.03-133.660.0262---87.06-37.78-237.07------
Medicofarma Biotech SA281.45k-3.06m33.99m24.00--7.14--120.76-0.0450-0.04500.00410.070.019966.640.746911,727.08-21.55-14.96-31.48-18.5938.8036.02-1,085.51-64.020.821-11.710.00--63.14-17.3933.11------
GENOMED SA27.49m3.27m41.22m53.0012.603.3110.231.502.482.4820.819.422.215.1712.68509,166.1026.317.5128.798.8165.2462.3311.903.847.51--0.00--2.343.1819.321.9815.97--
Sds Optic SA7.44m-483.71k48.51m41.00--49.40220.256.52-0.0815-0.08151.250.15590.54975.12125.84181,486.60-4.01-32.89-4.24-41.3598.1949.49-7.29-136.622.500.62780.00--40.53301.05-45.06--57.27--
Sygnis SA7.73m-6.34m57.60m12.00--1.79--7.45-0.2499-0.24990.33091.170.1166-0.16896.14218,427.70-9.03-8.61-15.00-12.10108.4959.85-77.44-39.140.6697-0.00660.13---52.2926.88-47.44---9.50--
Read Gene SA15.19m-887.46k66.26m11.00--24.73--4.36-0.0536-0.05361.170.22731.0839.776.30---6.32-2.40-6.88-2.7492.6390.21-5.84-4.306.31-0.6960.00--30.3826.3817.49------
Genomtec SA15.00k-11.01m75.17m----7.26--5,011.50-0.7485-0.74850.0010.68690.0009--0.0143---65.47-89.96-82.11-113.38-54,120.00-4,379.72-73,393.34-17,225.072.82-39.820.1409--0.00-63.42-24.35---34.54--
Urteste SA0.00-5.47m77.83m34.00--3.32-----3.88-3.880.0015.350.00-------15.56-29.65-18.99-31.35---45,933.33---623,333.30----0.0128------35.00--197.79--
Hyenergy SA3.29m169.85k77.91m27.00--3.95318.9023.69-0.0936-0.09360.16540.58780.18210.12590.7741--0.94032.391.283.3599.7077.465.163.111.301.170.00--192.8319.47100.30---45.79--
Nanogroup SA-6.90k-6.93m87.65m----7.51-----0.1844-0.1844-0.00020.3553-0.00032.64-----30.59-29.50-51.55-33.80--66.72---2,258.260.9785-464.180.00--3.96-64.0934.50--3.07--
Poltreg SA0.00-24.56m127.31m33.00--2.57-----5.27-5.270.0010.610.0016.45--0.00-25.87-9.02-29.62-10.18---659.36---854.232.65--0.1365---74.98-6.89-38.06--83.47--
Mabion SA14.81m-59.30m132.53m204.00--1.89--8.95-3.67-3.670.91644.330.09888.1027.2572,602.94-39.560.5366-54.811.06-178.5558.34-400.370.96430.2276--0.04---54.50---115.35--6.00--
Molecure SA5.11m-24.42m151.85m71.00--1.70--29.70-1.20-1.200.24934.340.0553--7.0150,119.41-26.42-3.15-27.53-3.3051.4893.34-477.67-15.45----0.0588---40.47278.20-10.27--12.49--
Data as of Feb 16 2026. Currency figures normalised to Sygnis SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.